Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05747196

The Safety and Feasibility of the eLym™ System

Led by WhiteSwell, Limited · Updated on 2026-01-07

70

Participants Needed

11

Research Sites

196 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this feasibility study is to evaluated the safety and performance of the WhiteSwell eLym System in the treatment of fluid overload or congestion in adult patients with Acute Decompensated Heart Failure (ADHF). The main question\[s\] it aims to answer are: * Acute device safety (30 days) * Chronic device safety (31-180 days) * Primary performance Outcomes (Technical success and patient treatment outcomes) Participants who are hospitalized for ADHF will be screened for treatment with the eLym System. The System, placed in a heart catheterization laboratory, will be temporarily placed for up to 60 hours to treat congestion. The patient will be followed during the hospital stay through discharge and have follow-up assessments at 30-, 60-, 90- and 180-days.

CONDITIONS

Official Title

The Safety and Feasibility of the eLym™ System

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Hospitalized with a primary diagnosis of Acute Decompensated Heart Failure (ADHF)
  • Receiving intravenous diuretics for fluid overload with peripheral edema 2+ or more and at least one of: jugular venous distension 10 cm H20 or more, pulmonary edema by exam or imaging, hepatojugular reflux, paroxysmal nocturnal dyspnea or two-pillow orthopnea, or dyspnea at rest with respiratory rate 20 or more
  • Total daily diuretic dose prior to admission of 80 mg Lasix or equivalent
  • Estimated glomerular filtration rate (eGFR) of 20 ml/min/1.73m2 or higher
  • Meets one of the following: recent heart failure hospitalization or worsening requiring IV diuretics within 6 months; eGFR between 20 and 45 ml/min/1.73m2; urine output less than 600 ml within 6 hours of initial IV bolus or urine sodium less than 50 mmol/L 1-2 hours after initial IV diuretic dose
  • Elevated NT Pro BNP (>1000 pg/ml, >1500 if atrial fibrillation) or BNP (>250 pg/ml, >375 if atrial fibrillation)
  • Albumin level greater than 2.5 g/dL
  • Able to have device placed within 96 hours of hospital presentation and still show fluid overload
  • Willing and able to complete study assessments and follow-ups
  • Provided written informed consent
Not Eligible

You will not qualify if you...

  • Anatomy not compatible with the eLym system device dimensions
  • Need for intravenous vasoactive drugs, mechanical ventilation, mechanical circulatory support, or ultrafiltration
  • Thromboembolic event (e.g., pulmonary embolism, deep vein thrombosis, TIA, stroke) within past 6 months
  • Contraindications to systemic anticoagulation
  • Currently taking Dabigatran
  • International Normalized Ratio (INR) over 2.2 not due to anticoagulation therapy or hypercoagulable states
  • Previous intracranial bleeding unless safe anticoagulation use documented
  • Gastrointestinal bleeding within 6 months requiring hospital stay or transfusion
  • Major surgery within 30 days with increased bleeding risk
  • Platelet count below 75,000 per microliter
  • Unable to tolerate anticoagulation therapy for 3 days
  • Systolic blood pressure below 85 mmHg at enrollment
  • Severe liver disease, liver fibrosis, or hepatorenal syndrome
  • Active bloodstream infection or pneumonia
  • Sustained malignant arrhythmias in last 90 days
  • Acute coronary syndrome in last 3 months
  • Severe other diseases likely to prolong hospitalization or cause death within 90 days
  • Rhythm management device implanted within last 45 days
  • Pregnant or lactating women; women of childbearing potential must have negative pregnancy test
  • Physician discretion

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 11 locations

1

Israeli-Georgian Medical Research Clinical Helsicore

Tbilisi, Georgia, Georgia, 0112

Terminated

2

Tbilisi Heart and Vascular Center

Tbilisi, Georgia, Georgia, 0159

Actively Recruiting

3

Tbilisi Heart Centre

Tbilisi, Georgia, Georgia, 0186

Actively Recruiting

4

Wroclaw University Hospital and Clinics

Wroclaw, Poland, 50-556

Actively Recruiting

5

Hospital Clinic de Barcelona

Barcelona, Spain, Spain

Actively Recruiting

6

Germans Trias i Pujol Hospital

Badalona, Spain, 08916

Actively Recruiting

7

Hospital 12 de Octubre

Madrid, Spain

Actively Recruiting

8

Hospital Universitario Puerta de Hierro Majadahonda

Majadahonda, Spain

Actively Recruiting

9

Hospital Clinico San Carlos

San Carlos, Spain

Actively Recruiting

10

Hospital Clinico Universitario de Valencia

Valencia, Spain, 46010

Actively Recruiting

11

Hospital Clínico de Valladolid

Valladolid, Spain

Actively Recruiting

Loading map...

Research Team

S

Sergio Shkurovich

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DEVICE_FEASIBILITY

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here